INDICATION
Dyspeptic symptom complex, often associated with delayed gastric emptying,
gastro-esophageal reflux and esophagitis: Epigastric sense of fullness, feeling
of abdominal distension, upper abdominal pain, eructation, flatulence, early
satiety, nausea and vomiting, heartburn with or without regurgitations of
gastric contents in the mouth, diabetic gastroparesis, non-ulcer dyspepsia
Nausea and vomiting: Acute nausea and vomiting of functional, organic,
infectious, dietetic origin or induced by radiotherapy or drug therapy or
induced in migraine.
Parkinson’s disease: In dopamine-agonist induced nausea and vomiting.
Radiological studies: Speeding barium transit in follow-through
radiological studies.
DOSAGE AND ADMINISTRATION
Motigut® should be taken 15-30 minutes before meals and, if necessary,
before retiring.
The usual recommended oral dose is as follow:
Adults: 10-20 mg (1-2 tablet or 10-20 ml suspension) every 4-8 hours daily.
Children: 0.2-0.4 mg/kg (2-4 ml suspension/ 10 kg) body weight every 4-8
hours daily.
In dyspeptic symptom:
The recommended oral dose for
Adults: 10-20 mg (1-2 tablet or 10-20 ml suspension), every 4-8 hours daily.
Children: 2-4 ml suspension /10 kg body weight, every 4-8 hours daily.
In acute and sub-acute conditions (mainly in acute nausea and
vomiting): In acute nausea and vomiting maximum period of treatment is 12
weeks. The recommended oral dose for
Adults: 20 mg (2 tablet or 20 ml suspension), every 4-8 hours daily.
Children: 0.3 mg/kg (3 ml suspension /10 kg) body weight, every 4-8 hours
daily.
CONTRAINDICATION AND PRECAUTION
Domperidone is contraindicated to patients having known hypersensitivity
to this drug and in case of neonates. Domperidone should not be used
whenever gastro-intestinal stimulation might be dangerous i.e. gastrointestinal
hemorrhage, mechanical obstruction or perforation. Also
contraindicated in patients with prolactin releasing pituitary tumor
(prolactinoma).
Domperidone should be used with absolute caution in case of children
because there may be increased risk of extra-pyramidal reactions in young
children because of an incompletely developed blood-brain barrier. Since
domperidone is highly metabolized in liver, it should be used with caution in
patient with hepatic impairment.
SIDE EFFECT
Domperidone may produce hyperprolactinemia (1.3%). This may result in
galactorrhea, breast enlargement, and soreness and reduced libido. Dry
mouth (1%), thirst, headache (1.2%), nervousness, drowsiness (0.4%),
diarrhea (0.2%), skin rash and itching (0.1%) may occur during treatment
with domperidone. Extra-pyramidal reactions are seen in 0.05% of patients
in clinical studies.
DRUG INTERACTION
Domperidone may reduce the risk of hypoprolactemic effect of
bromocriptine. The action of Domperidone on GI function may be
antagonized by anti-muscarinics and opoid analgesics. Care should be
exercised when domperidone is administered in combination with MAO
(monoamine oxidase) inhibitors.
USE IN PREGNANCY AND LACTATION
Pregnant women: The safety of domperidone has not been proven and it is
therefore not recommended during pregnancy. Animal studies have not
demonstrated teratogenic effect in the fetus.
Lactating mother: Domperidone may precipitate galactorrhea and improve
post-natal lactation. It is secreted in breast milk but in very small quantities
insufficient to be considered harmful.
Reviews
There are no reviews yet.